Repligen to Acquire BioLife Solutions in $1.5B Deal, Expanding Cell Therapy Capabilities
RGEN sits 30% above its 52-week low of $100.99 on elevated volume (1.9× avg).
Summary
Repligen announced a definitive agreement to acquire BioLife Solutions for $1.5 billion in cash and stock, adding a market-leading biopreservation media platform and accelerating its cell therapy strategy. The deal is expected to be accretive to adjusted EPS by at least 5 cents in year one and 25 cents in year two, with over $20 million in year-one synergies.
Key Events · M&A and Partnerships · RGEN
-
Acquisition of BioLife Solutions
Repligen will acquire BioLife Solutions for $11.25 cash and 0.1442 shares of Repligen common stock per BioLife share, valuing BioLife at $31.00 per share and a total enterprise value of approximately $1.5 billion.
-
Financial Impact and Synergies
The transaction is expected to be accretive to adjusted EPS by at least 5 cents in year one and 25 cents in year two, with at least $20 million in year-one synergies from public company cost elimination, G&A efficiencies, and supply chain optimization.
-
Strategic Rationale
BioLife's biopreservation media platform, led by CryoStor, is embedded in 18 commercially approved cell therapies and the majority of U.S. cell-based therapy trials, fast-tracking Repligen's leadership in the >20% CAGR cell therapy market.
-
Preliminary Q2 2026 Results
Repligen reported preliminary Q2 revenue growth of ~12% as reported (13% organic), with strong margin expansion; BioLife reported preliminary Q2 revenue of $28.5 million, up 21% year-over-year.
Analysis · RGEN · Life Sciences
Repligen is acquiring BioLife Solutions for $1.5 billion in a cash-and-stock deal that significantly expands its presence in the high-growth cell therapy market. The acquisition adds a differentiated biopreservation media platform with deeply embedded customer relationships and high-margin recurring revenue. Financially, the deal is expected to be immediately accretive to growth, margins, and adjusted EPS, with clear synergy targets. The transaction transforms Repligen's cell therapy offering and is likely to be viewed as a strategically sound, financially disciplined move that strengthens its competitive position.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 41.2% of the 452 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RGEN was trading at $131.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.7B. The 52-week trading range was $100.99 to $175.77. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.